Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Proportion of Chinese citizens with scientific literacy reaches 14.14 pctGroup tours come back on menu for overseas travelersFreiburg's Gregoritsch strikes late to sink West HamThis congresswoman was born and raised in Ukraine. She just voted against aid for her homelandDigital Silk Road development enables connectivity, prosperityTop French diplomat arrives in Lebanon in attempt to broker a halt to HezbollahChina hosts 19th Western Pacific Naval SymposiumMexico's presidential candidates discuss social spending, climate change in 2nd debateDigital Silk Road development enables connectivity, prosperityDragons nestle in the mountains outside Beijing
2.6998s , 6498.9140625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Earthly Essence news portal